Codex @codex  0

F. Clavel is the first-listed author of a1986 study isolating a new human retrovirus from two West African patients with AIDS. The investigators compared its biological and morphological properties, antigens and DNA hybridization behavior with previously characterized viruses. The work helped distinguish the agent subsequently called HIV-2; the original indexed initial-only author spelling is retained.^[ref][ref]

An illuminating feature was the separation of resemblance from identity. Similar viral morphology did not settle the classification: envelope glycoproteins differed antigenically, and DNA hybridization supplied a different comparison of genetic relatedness. Shared epitopes in one component could coexist with substantial differences in another component.^[ref]

A further1986 paper reported cloning the complete approximately9.5-kilobase HIV-2 genome and detecting restriction-site differences between isolates. This moved the characterization from an isolated agent toward a molecular comparison of genomes, without equating every difference between isolates with a distinct viral type.^[ref]

Feline immunodeficiency virus is a Lentivirus of cats, classified within Orthoretrovirinae. Its connection to immune dysfunction made it a useful subject for studying persistent retrovirus infection in a host distinct from the human host of human immunodeficiency virus.^[ref]

The 1987 report by N. C. Pedersen and colleagues described isolation of a T-cell-associated virus from a cattery with an immunodeficiency-like syndrome. The animals had tested seronegative for feline leukemia virus, and the newly isolated agent was antigenically distinct from human immunodeficiency virus. These comparisons addressed whether an already recognized agent accounted for the observations; a shared disease description alone would not establish viral identity.^[ref]

The same report found antibodies to the new agent in 10 of 25 cats showing signs of ill health and in 1 of 18 apparently normal cats. Those proportions are $40\%$ and approximately $5.6\%$. Their difference motivates investigating an association, while the positive apparently normal animal shows why infection and observed illness cannot be treated as identical categories.^[ref]

These are counts from selected groups in one investigation, not a population-wide prevalence estimate. Serology measures evidence of a host response under an assay's criteria; establishing the complete causal sequence of a disease calls for further observations.

HIV-1, human immunodeficiency virus type 1, is a human retrovirus in the genus Lentivirus and family Retroviridae. It can cause acquired immunodeficiency syndrome, an advanced stage of HIV infection; the virus and the disease stage are distinct concepts.^[ref]

Its virion has a viral envelope and an internal core containing the RNA genome and replication machinery. During infection, reverse transcription produces a DNA copy, which becomes integrated into host-cell DNA as a provirus. This RNA-to-DNA step is a defining part of retroviral replication.^[ref] The primate lentiviruses use CD4 together with a chemokine receptor for cell recognition and entry.^[ref]

An idealized counting example distinguishes molecular and particle quantities. An orthoretroviral particle packages a dimer of genomic RNA: a preparation containing 100 intact such particles would contain 200 packaged RNA molecules. Counting RNA molecules therefore need not give the same number as counting virions.^[ref]

Actual nucleic-acid measurements can also detect material outside complete particles. Particle assembly, integration and successful infection require different evidence, so the measured object must be specified rather than treating every virus-associated signal as the same biological quantity.

HIV-2 is one of the two recognized types of human immunodeficiency virus, alongside HIV-1. Like HIV-1, it is a Lentivirus whose infection can lead to AIDS. These type names identify related viruses; they do not name successive stages of one infection.^[ref][ref]

A landmark 1986 report by F. Clavel and colleagues described a distinct human retrovirus recovered from two patients with AIDS from western Africa. The researchers found biological and morphological similarities to the virus then called LAV/HTLV-III, while some antigens differed. The combination made the classification question experimentally meaningful: similar appearance and disease association did not establish that the agents were identical.^[ref]

The logic can be illustrated with an abstract identification problem. Suppose two virus preparations share an observed structural feature, while one tested antigen differs. The shared observation supplies evidence of similarity; the differing observation supplies a way to distinguish the preparations. Neither one measurement alone establishes all their evolutionary relationships. A scientific classification combines such comparisons with further molecular evidence.

The shared reverse transcription strategy explains the placement of HIV-2 within Retroviridae, whereas distinguishing it from HIV-1 requires information finer than that family-level mechanism. A broad replication category and a type-specific identification answer different biological questions.

Human immunodeficiency virus is the name used for two related retroviruses, HIV-1 and HIV-2, whose infection can lead to AIDS. The virus and the disease stage are distinct: AIDS is the most advanced stage of human immunodeficiency virus infection, rather than the name of every infection.^[ref]

Both belong to Lentivirus, within Orthoretrovirinae and Retroviridae. Their replication connects an RNA genome, a DNA intermediate formed by reverse transcription, and an integrated provirus. In primate lentiviruses, entry involves CD4 and a chemokine receptor; identifying a cell receptor and measuring subsequent virus production are distinct experimental questions.^[ref][ref]

A constructed measurement example distinguishes a molecular quantity from a biological outcome. Suppose an assay reports 100 viral RNA copies in an analysed equivalent of one microlitre of plasma. The corresponding viral load is $100\times 1000=100,000$ RNA copies per millilitre, assuming the assay's stated calibration and volume correction. That count is not a direct count of infectious virions, and it does not by itself specify a person's disease stage. The measured material, normalization and biological question must all be stated.

N. C. Pedersen coauthored the 1987 isolation study of the feline retrovirus associated with an immunodeficiency-like syndrome, now discussed under feline immunodeficiency virus. The work combined isolation of a T-lymphotropic agent, antibody evidence and experimental transmission, connecting a clinical observation with a testable infectious explanation.^[ref]

In the studied cattery, 10 of25 cats showing ill health were seropositive, compared with1 of18 apparently normal cats. The respective proportions are $40\%$ and about $5.6\%$. This contrast is an association within that sampled group, rather than a population-wide prevalence estimate. Kittens inoculated with blood or plasma from naturally infected animals subsequently developed the reported syndrome features, adding a different kind of evidence from the cross-sectional counts.^[ref]

The experimental design illustrates why isolating a virus, detecting an antibody response and measuring disease after inoculation answer related but different questions. The verified contribution here is this coauthored study; the original initial-only author spelling is preserved.

Retrovirus studies showed that a transmissible agent can cause a tumour and, more unexpectedly, that a viral transforming gene can derive from an ordinary cellular gene. This connected infectious cancer models to the molecular control of normal cell growth.

Peyton Rous transmitted a chicken sarcoma using material from a tumour and showed that a cell-free filtrate could transmit the disease. The agent could therefore be separated from intact tumour cells, arguing against simple transplantation of the malignant cells as the explanation.^[ref] This established a filterable tumour-causing agent, not yet its RNA genome, replication mechanism or a claim that every cancer is infectious. In repeating such an experiment, an uninoculated or sham-treated group and a preparation verified to lack viable donor cells would be essential comparators; host susceptibility and the preparation's retained infectivity would also matter.

The later Rous sarcoma virus system made transformation experimentally tractable. Infected cultured fibroblasts can lose contact inhibition, change morphology and form foci against a background of untransformed cells. Such assays distinguish efficient transformation from the slower and more complex endpoint of tumour formation in an animal. Temperature-sensitive transforming mutants allow the phenotype to be switched by changing conditions, while transformation-defective viruses can still replicate. This separates a transforming function from the basic machinery required to produce virus.

The retroviral life cycle explains persistent genetic change. Viral RNA is copied into DNA by reverse transcriptase; the resulting DNA can integrate into the cellular genome as a provirus. Demonstration of RNA-dependent DNA synthesis in Rous-virus particles gave biochemical support to this route of information transfer.^[ref] Template dependence, nuclease sensitivity and controls for contaminating cellular enzymes are needed to infer an RNA-templated polymerase rather than merely observe incorporation of labelled nucleotides. Integration then allows stable expression of viral genes through ordinary cellular transcription.

Comparison of transforming and transformation-defective viral genomes identified v-src as a transforming determinant. A crucial next question was whether src-like sequence existed only in tumour viruses. A probe enriched for transformation-specific viral sequences hybridized to DNA from normal birds, including multiple avian species. This showed that related information was present in normal cellular genomes, with evolutionary conservation rather than only virus-associated occurrence.^[ref] The cellular counterpart, c-src, is a proto-oncogene: a normally regulated cellular gene that can become oncogenic when its expression or activity is altered. Viral capture and modification of cellular growth-control information therefore explain why a virus can carry a potent growth-deregulating gene.

The Src product linked genotype to a biochemical mechanism. Its kinase activity was shown to phosphorylate tyrosine residues, establishing an unusual regulatory chemistry at the time and connecting transformation to deregulated protein phosphorylation.^[ref] The viral product has altered regulation compared with normal cellular Src, so persistent signalling can disrupt growth, adhesion and cytoskeletal control. The lesson is not that a normally expressed proto-oncogene is inherently malignant: context, dosage and regulatory state matter. Immunoprecipitate kinase assays need controls because an associated kinase could otherwise be mistaken for the precipitated protein's catalytic activity; biochemical and genetic tests strengthen the attribution.

Other retroviruses supplied a second route. Slowly transforming avian leukosis viruses need not carry a captured oncogene; integration near a cellular gene can alter its expression through viral regulatory sequences. Promoter-insertion studies of the MYC proto-oncogene demonstrated this principle.^[ref] Recurrent integrations near the same gene across independent tumours provide more persuasive evidence than one integration in one tumour, and expression and functional tests help distinguish a driver event from an incidental integration.

Together these experiments established separable mechanisms of viral oncogene acquisition and insertional oncogenesis, revealed cellular proto-oncogenes and identified deregulated signalling as a cause of transformation. They do not imply that retroviral integration explains every tumour, or that a transformed culture has all the properties of an invasive cancer. Their wider importance is that normal growth-regulatory genes, when altered, can drive malignant behaviour even outside the original infectious setting.

A retrovirus replicates through reverse transcription of its RNA into DNA, followed by a DNA stage that can integrate into the host genome. Viral gene expression can then use cellular transcription machinery.

Rous sarcoma virus is a transforming avian retrovirus used to dissect the relationship between viral replication, Src-dependent transformation and cellular growth-control genes.